JPH05507501A - リンパ球応答と免疫関連疾患との阻害剤 - Google Patents

リンパ球応答と免疫関連疾患との阻害剤

Info

Publication number
JPH05507501A
JPH05507501A JP91517849A JP51784991A JPH05507501A JP H05507501 A JPH05507501 A JP H05507501A JP 91517849 A JP91517849 A JP 91517849A JP 51784991 A JP51784991 A JP 51784991A JP H05507501 A JPH05507501 A JP H05507501A
Authority
JP
Japan
Prior art keywords
peptide
amino acid
cells
peptides
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP91517849A
Other languages
English (en)
Japanese (ja)
Inventor
ウイリエム・ファン・エデン
マルシャ・エイチ・エム・ヴァウベン
ルード・ファン・デル・ゼー
クレア・ジェイ・ピー・ボーグ
アイラン・アール・コーエン
Original Assignee
リックスウーニーベルシテイト・テ・ウットレヒト
イエダ・リサーチ・アンド・デベロップメント
デイ・スタート・デル・ネーデルランデン　フェアテエーゲンブォディックト・ドール・デ　ミニスター・ファン・ベルジージン　フォルクスゲッツゾーンドハイド　エンクルトウア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リックスウーニーベルシテイト・テ・ウットレヒト, イエダ・リサーチ・アンド・デベロップメント, デイ・スタート・デル・ネーデルランデン　フェアテエーゲンブォディックト・ドール・デ　ミニスター・ファン・ベルジージン　フォルクスゲッツゾーンドハイド　エンクルトウア filed Critical リックスウーニーベルシテイト・テ・ウットレヒト
Publication of JPH05507501A publication Critical patent/JPH05507501A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP91517849A 1990-09-06 1991-09-05 リンパ球応答と免疫関連疾患との阻害剤 Pending JPH05507501A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57850690A 1990-09-06 1990-09-06
US578,506 1990-09-06
PCT/US1991/006434 WO1992004049A1 (en) 1990-09-06 1991-09-05 Inhibitor of lymphocyte response and immune-related disease

Publications (1)

Publication Number Publication Date
JPH05507501A true JPH05507501A (ja) 1993-10-28

Family

ID=24313172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP91517849A Pending JPH05507501A (ja) 1990-09-06 1991-09-05 リンパ球応答と免疫関連疾患との阻害剤

Country Status (8)

Country Link
EP (1) EP0503055A1 (xx)
JP (1) JPH05507501A (xx)
AU (1) AU650065B2 (xx)
CA (1) CA2071896A1 (xx)
IL (1) IL99429A0 (xx)
NZ (1) NZ239699A (xx)
WO (1) WO1992004049A1 (xx)
ZA (1) ZA917097B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
CA2185826C (en) * 1994-03-21 2007-06-19 Stephen Mark Anderton Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
GB9419553D0 (en) * 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
IT1271074B (it) * 1994-11-21 1997-05-26 Italfarmaco Spa Peptidi ad attivita' antiinfiammatoria
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
KR20000070460A (ko) * 1997-01-24 2000-11-25 왈리스 조 앤 메토트렉세이트와 공동으로 내성화를 사용한 자기면역질병의 치료
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
WO2003063759A2 (en) 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
ES2433915T3 (es) 2002-05-21 2013-12-13 Irun R. Cohen Vacunas de ADN que codifican proteínas de choque térmico
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, PEPTIDES HSP60 AND T-CELL VACCINES FOR IMMUNOMODULATION

Also Published As

Publication number Publication date
CA2071896A1 (en) 1992-03-07
WO1992004049A1 (en) 1992-03-19
AU8755991A (en) 1992-03-30
ZA917097B (en) 1992-09-30
IL99429A0 (en) 1992-08-18
EP0503055A4 (xx) 1994-02-16
AU650065B2 (en) 1994-06-09
EP0503055A1 (en) 1992-09-16
NZ239699A (en) 1993-11-25

Similar Documents

Publication Publication Date Title
Sakai et al. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.
Wauben et al. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone.
EP0359783B1 (en) Treatment of autoimmune diseases by oral administration of autoantigens
JP2635444B2 (ja) 自己抗体の経口投与による自己免疫性疾患の治療
US20060159672A1 (en) Identification of self and non-self antigens implicated in autoimmune diseases
Kaumaya et al. Peptide vaccines incorporating a ‘promiscuous’ T‐cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity
Ragno et al. A synthetic 10-kD heat shock protein (hsp10) from Mycobacterium tuberculosis modulates adjuvant arthritis
Wraith et al. Cross-reactive antigen recognition by an encephalitogenic T cell receptor. Implications for T cell biology and autoimmunity.
EP0914333B1 (en) Peptide derivatives
JPH05507501A (ja) リンパ球応答と免疫関連疾患との阻害剤
IL194987A (en) Use of PIF peptide to produce a drug to regulate the immune system
US20020058787A1 (en) Mhc binding peptide oligomers and methods of use
Yang et al. Prevention of adjuvant arthritis in rats by a nonapeptide from the 65-kD mycobacterial heat-shock protein
US6087336A (en) Peptide derivatives useful in treating autoimmune diseases
US6355617B1 (en) Peptide derivatives
Miyahara et al. Identification and characterization of a major tolerogenic T-cell epitope of type II collagen that suppresses arthritis in B10. RIII mice.
JP2010235607A (ja) 自己免疫疾患の診断薬と治療薬となるペプチド類
US6207644B1 (en) Peptide analogues containing a 7-membered lactam ring
JP4065322B2 (ja) 合成ペプチドおよびそれらを含有する医薬組成物
Rosloniec et al. Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models
EP1064006A1 (en) Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
Sitaraman Myasthenia gravis: Role of cytokines in disease and design of therapy